Document Detail


Effects of trimetazidine on submaximal exercise test in patients with acute myocardial infarction.
MedLine Citation:
PMID:  14696632     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: It was demonstrated that the novel metabolic agent, trimetazidine, could lessen the incidence and severity of angina, whether used in monotherapy or combination. Although the animal studies demonstrated that trimetazidine reduces myocardial infarct size anf improves recovery of mechanic function after ischemia, little is known on the potential benefits of trimetazidine in patients with myocardial infarction (AMI). The aim of this study was to evaluate the efficacy of trimetazidine on AMI by sub-maximal exercise test. METHODS: A double-blind crossover trimetazidine versus placebo trial was carried out in 44 patients with AMI. Patients with randomly allotted into trimetazidine (23 patients) or placebo (21 patients) for 5 days and underwent an initial sub-maximal exercise test. Exercise tests according to the modified Bruce protocol were performed. Exercise end points included completion of stage II or 75% of maximum predicted heart rate whichever came first. An average 12-lead ECG was obtained at rest, every minute during exercise, at the onset of anginal symptoms, at the onset of 1-mm ST segment depression, at peak exercise and every 2-minute during recovery. After the initial exercise tests, study groups resumed the drugs in the opposite order for 4 to 5 days and underwent a second sub-maximal exercise test. RESULTS: Exercise induced ST segment depression was noted in 17 patients (38.6%) receiving placebo. However, exercise induced ST-segment depression was observed in 8 patients (18.1%) taking TMZ. Positive exercise test results were significantly higher on placebo group than TMZ group (p=0.018). Additionally, trimetazidine prolonged the time to 1-mm ST-segment depression (6.1 +/-0.5 vs 4.9 +/-0.4, P< 0.031) and exercise duration (7.2+/-0.9 vs 5.8 +/-0.9, p<0.025). CONCLUSION: Trimetazidine therapy improves the exercise capacity and reduces evidence ischemia derived from sub-maximal post-infarction exercise testing.
Authors:
Niyazi Güler; Beyhan Eryonucu; Ahmet Günes; Unal Güntekin; Mustafa Tuncer; Hanefi Ozbek
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  17     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  2003 Jul 
Date Detail:
Created Date:  2003-12-29     Completed Date:  2004-05-19     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  371-4     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Medical Faculty, Yüzüncü Ytl University, Van, Turkey. niyaziguler@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cross-Over Studies
Double-Blind Method
Exercise Test / drug effects*
Female
Humans
Male
Middle Aged
Myocardial Infarction / drug therapy*
Trimetazidine / therapeutic use*
Vasodilator Agents / therapeutic use*
Chemical
Reg. No./Substance:
0/Vasodilator Agents; 5011-34-7/Trimetazidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carbachol prolongs ventricular repolarisation through nitric oxide release in an intact heart.
Next Document:  Low-dose systemic phosphodiesterase III inhibitor pimobendan combined with prostacyclin therapy in a...